Cite
HARVARD Citation
Wanzel, M. et al. (n.d.). CRISPR-Cas9-based target validation for p53-reactivating model compounds. European journal of cancer. pp. S122-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Wanzel, M. et al. (n.d.). CRISPR-Cas9-based target validation for p53-reactivating model compounds. European journal of cancer. pp. S122-. [Online].